Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition

ContinUse Biometrics, dba Donisi Health, Donis

PR93561

 

TEL AVIV, Israel, December 10, 2021 /PRNewswire=KYODO JBN/--

 

MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart

Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and

$200,000 Award

 

Donisi Health [https://donisihealth.com/](Donisi) prevailed in this year’s ICI

Innovation Competition – the premier international conference for innovations

in cardiovascular intervention.  Competing against startups from all over the

world in front of a panel of twenty industry expert judges, Donisi took home

First Place honors and a $200,000 award for their innovative solution to enable

in-home monitoring for key health bio-markers for patients with Congestive

Heart Failure (CHF) and other chronic diseases.

 

Donisi has the only clinically validated, contact-free technology that can

detect signs of pulmonary congestion remotely, supporting the continuum of care

for remote patient monitoring and hospital-at-home services.  Based upon

FDA-cleared technology and backed by 11 granted patents, Donisi’s AI-based

system detects and analyzes multiple health bio-indicators simultaneously -

without the need to remove clothing or connect the patient to wires or patches

- delivering clinically meaningful insights and notifications of changes in key

health indicators.

 

“We are honored to be recognized  by this prestigious institution, and are

grateful to the ICI team for highlighting our breakthrough technology’s

potential to meaningfully improve cardiovascular health,” said Donisi’s CEO

Yair Brosh.  “We are focused on developing solutions for chronic patients at

home, with a goal to reduce readmission rates for CHF patients..”

 

In the United States, CHF is the #1 cause of readmission among Medicare (65+)

patients, with at least 20% of patients readmitted within 30 days and 50%

within 6 months.  With an average cost of readmissions in the tens of thousands

of dollars per patient, direct medical costs for CHF in the US total over $21.7

billion annually.

 

”This doesn’t need to be the case,” said Donisi’s new Chief Medical Officer,

Dr. Shaddy Hassan. “It is known that when heart failure exacerbations are

detected early, and healthcare teams intervene while patients are still at home

before their condition worsens, many of these costly readmissions can be

avoided, resulting in significant cost reduction and improved quality of life.”

 

This award marks the latest in a highly successful year for the HealthTech

Startup beginning with a $1M BIRD grant [

https://www.calcalistech.com/ctech/articles/0,7340,L-3888593,00.html?fbclid=IwAR1ids7FCSMPmZes-KkuPHgNfinKUM34uLPvgwjEJQqyYJ2PX8T4Y6S_e9w]

awarded in partnership with Dell Technologies in January, scientific article

publication [

https://www.tandfonline.com/doi/abs/10.1080/03091902.2021.1905896?journalCode=ijmt20],

a de novo FDA clearance and First Place at MEDinISRAEL

[https://vimeo.com/535866905] in April, and Future Unicorn award by E&T

Magazine [

https://finance.yahoo.com/news/donisi-health-named-2021s-future-105300198.html?.tsrc=fin-srch],

among others.

 

For more information please contact:

Hannah Carimi

Donisi Health, Israel

hannah.carimi@donisihealth.com

 

Michael Seggev

Donisi Health, US

michael.seggev@donisihealth.com

 

Photo - https://mma.prnewswire.com/media/1705485/Donisi_Health_Wins_ICI.jpg

 

Source: ContinUse Biometrics, dba Donisi Health, Donis

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中